Momeone Nasal Spray (Mometasone Furoate)

Adult use

1. Allergic rhinitis Adults (including the elderly) and adolescents aged 12 years and older: generally 1 spray to each nostril twice daily (total daily dose of 0.2 mg). When symptoms improve, the maintenance dose can be reduced to 1 spray to each nostril once daily (total daily dose of 0.1 mg). If symptoms do not improve, the dose can be increased to a maximum of 4 sprays to each nostril once daily (total daily dose of 0.4 mg).

Child use

Children aged 2 to 11 years: generally 1 spray to each nostril once daily (total daily dose of 0.1 mg).

This drug should not be used in certain patients. For instance, those who are allergic to this drug or its components, have infections of the nasal mucosa, have recently undergone nasal surgery, have wounds in the nose, and children under 2 years of age should not use this drug. Additionally, patients with tuberculosis, fungal or viral infections, those with herpes simplex in the eye, frequent nosebleeds, those exposed to chickenpox or measles, those with certain types of tumors in the nose, and pregnant or breastfeeding women should use this drug cautiously. While using this medication, side effects such as headaches, cold symptoms, nosebleeds, cough, and sore throat may occur. Rarely, severe reactions such as allergic responses or anaphylaxis may occur, so if unusual symptoms appear, use should be discontinued immediately and consult a doctor. Caution is needed for long-term high-dose use as systemic steroid side effects may appear. If nasal infection symptoms appear, this medication may need to be stopped or appropriate treatment may be required. This drug tends to restore the nasal mucosa without damaging it, but regular checks on the nasal condition should be carried out if used long-term. In particular, if there is a risk of exposure to infectious diseases such as chickenpox or measles, one should confirm vaccination history and medical history and inform healthcare professionals immediately if an infection occurs. In children, there may be a risk of growth delay, so growth should be regularly monitored during administration, and safety has not been established in children under 2 years of age. Elderly patients may have diminished body function, so use should be carefully monitored. Specific treatment is not required in the case of overdose, but caution should be used as excessive steroid use may lead to adrenal function decline. Before use, the container should be well shaken, and care should be taken to ensure even spraying, avoiding direct spraying onto the eyes or nasal septum. Keep out of reach of children, and the effects on driving or operating machinery are unknown.

Serious side effects

Hives, severe swelling (angioedema), chest tightness, difficulty breathing, cold sweat, paleness, severe allergic reactions, severe rash with high fever, blisters, skin peeling, pain in oral/ocular mucosa, severe skin adverse reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanying cough and fever, respiratory issues, jaundice (yellowing of the skin or eyes), extreme drowsiness, liver abnormalities (jaundice), sudden

Mild side effects

Headache, viral infection, pharyngitis, nosebleeds/blood-tinged mucus, cough, upper respiratory infection, menstrual discomfort, musculoskeletal pain, sinusitis, vomiting, arthralgia, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, dyspepsia, earache, cold symptoms, myalgia, nausea, rhinitis, diarrhea, nasal inflammation, otitis media, wheezing, skin trauma, nasal symptoms (irritation, itching, dryness, pain, redness, discomfort, etc.)

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 2 degrees and 25 degrees Celsius.

Appearance

An opaque suspension that is white or almost white in a container that dispenses a specified amount.

Package unit

18 milliliters/bottle